Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Torex is a combination oral cough syrup developed and marketed by Torque Pharmaceuticals. It is formulated with four active ingredients: diphenhydramine, ammonium chloride, terpin hydrate, and sodium citrate. Diphenhydramine serves as an antihistamine that blocks H1 receptors to alleviate allergy symptoms and reduce the sensitivity of the cough reflex. Ammonium chloride and terpin hydrate act as expectorants, increasing the volume and decreasing the viscosity of respiratory tract secretions to facilitate phlegm removal. Sodium citrate functions as a mucolytic agent that thins and loosens mucus. The product is indicated for the symptomatic relief of various cough types, including dry, chronic, and smoker's cough, and has been a leading brand in the Indian consumer healthcare market for over thirty years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Torex.